Accessibility StatementSkip Navigation PHILADELPHIA  , Nov. 24, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against Cepton, Inc. (NASDAQ: CPTN) ("Cepton" or the "Company") on behalf of investors who purchased or sold Cepton shares during the period of July 29, 2024 through January 6, 2025 (the "Class Period"). Investor Deadline: Investors who purchased or sold Cepton securities during the Class Period may, no later than December 8, 2025, seek to ...

Core Viewpoint - A class action lawsuit has been filed against MoonLake Immunotherapeutics for allegedly misleading investors regarding the efficacy of its drug candidate, sonelokimab (SLK), which reportedly failed to meet clinical benchmarks [1][3][4]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotech firm based in Zug, Switzerland, focusing on next-generation immunotherapies [2]. Legal Proceedings - The lawsuit is on behalf of investors who purchased MoonLake shares between March 10, 2024, and September 29, 2025, with a deadline of December 15, 2025, for investors to seek lead plaintiff status [1][2]. Drug Candidate Details - MoonLake promoted SLK as a breakthrough treatment due to its Nanobody structure but allegedly failed to disclose that it targets the same molecules as BIMZELX, an FDA-approved monoclonal antibody, indicating it was not clinically superior [3]. Trial Results and Market Impact - On September 28, 2025, MoonLake disclosed that SLK did not meet efficacy benchmarks in Phase 3 trials, leading to a significant stock price decline of $55.75 per share, nearly 90%, in one trading session [4].

Accessibility StatementSkip Navigation PHILADELPHIA, Nov. 17, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) ("MoonLake" or the "Company") on behalf of investors who purchased MoonLake shares during the period of March 10, 2024 through September 29, 2025 (the "Class Period"). Investor Deadline: Investors who purchased MoonLake securities during the Class Period may, no later than December 15, 2025, ...

Core Points - A class action lawsuit has been filed against Marex Group plc on behalf of investors who purchased shares between May 16, 2024, and August 5, 2025 [1][2] - The lawsuit alleges that Marex concealed losses and inflated profits through off-balance-sheet entities and fictitious transactions, leading to a significant drop in stock price [3] Company Overview - Marex Group plc is a London-based global financial services company specializing in trading, clearing, and risk management [2] Legal Context - Investors have until December 8, 2025, to seek appointment as lead plaintiff in the class action [2] - The lawsuit was triggered by a report from NINGI Research published on August 5, 2025, which accused Marex of financial misconduct [3]

Core Viewpoint - A class action lawsuit has been filed against MoonLake Immunotherapeutics for allegedly misleading investors regarding its drug candidate, sonelokimab (SLK), which was claimed to be superior to existing therapies but reportedly lacks demonstrated clinical advantages [3][4]. Company Overview - MoonLake Immunotherapeutics is a biopharmaceutical company based in Zug, Switzerland, focusing on therapies for inflammatory diseases [2]. Legal Action Details - The lawsuit is on behalf of investors who purchased MoonLake shares from March 10, 2024, to September 29, 2025, with a deadline of December 15, 2025, for investors to seek lead plaintiff status [1][2]. - The complaint alleges that MoonLake failed to disclose that SLK targets the same molecules as the FDA-approved drug BIMZELX, undermining claims of its clinical superiority [3]. Clinical Trial Outcome - On September 28, 2025, MoonLake disclosed that SLK did not achieve efficacy comparable to BIMZELX in Phase 3 clinical trials, leading to a significant stock price drop of $55.75 per share, nearly 90% in one trading day [4].

Accessibility StatementSkip Navigation PHILADELPHIA, Nov. 4, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against V.F. Corporation (NYSE: VFC) ("VFC" or the "Company") on behalf of investors who purchased or acquired shares during the period from October 30, 2023 through May 20, 2025 (the "Class Period"). Investor Deadline: Investors who purchased or acquired VFC securities during the Class Period may, no later than November 12, 2025, seek to be ...

Core Viewpoint - A class action lawsuit has been filed against Fluor Corporation (FLR) by Berger Montague on behalf of investors who acquired shares between February 18, 2025, and July 31, 2025, due to alleged misrepresentation of the company's financial condition and undisclosed issues with major infrastructure projects [1][3]. Company Overview - Fluor Corporation, headquartered in Irving, Texas, provides engineering, procurement, construction, and project management services globally, with its Urban Solutions segment being the largest revenue contributor [2]. Allegations and Investigation - The investigation focuses on claims that FLR misrepresented its financial health and concealed escalating issues related to significant infrastructure projects, including rising costs and delays in the Gordie Howe, I-635/LBJ, and I-35 projects [3]. Financial Performance - On August 1, 2025, FLR reported disappointing Q2 2025 results, with earnings per share (EPS) of $0.43 and revenue of $3.98 billion, missing consensus estimates by $0.13 and $570 million, respectively. The company reduced its full-year forecast, attributing the shortfall to project execution failures and a slowdown in new contract awards. Following this announcement, FLR's stock price fell over 27%, closing at $41.42 on the same day [4]. Market Reaction - In response to the negative news, several brokerages downgraded FLR's stock, citing significant concerns regarding the company's internal controls and transparency [5].

Core Viewpoint - A class action lawsuit has been filed against KBR, Inc. for allegedly making false and misleading statements regarding its partnership with HomeSafe, which led to a significant drop in KBR's stock price after the termination of a contract by the U.S. Department of Defense's TRANSCOM [1][3][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who acquired KBR shares between May 6, 2025, and June 19, 2025 [1][2]. - Investors have until November 18, 2025, to seek appointment as lead plaintiff representatives [2]. - The allegations include KBR's failure to disclose concerns from TRANSCOM about HomeSafe's ability to fulfill its obligations under the Global Household Goods Contract [3]. Group 2: Impact on Stock Price - Following the announcement of the contract termination by HomeSafe on June 19, 2025, KBR's shares fell by $3.85, or 7%, closing at $48.93 on June 20, 2025 [4]. Group 3: Company Background - KBR, headquartered in Houston, Texas, provides engineering, logistics, defense contracting, and mission-critical government services [2].

Core Viewpoint - A class action lawsuit has been filed against Sina Corporation, alleging that the company artificially depressed its share value during its go-private merger, impacting shareholders' ability to make informed decisions [1][3][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who sold Sina shares between October 13, 2020, and March 22, 2021, including those who sold during the go-private merger [1][2]. - Investors have until November 18, 2025, to seek appointment as lead plaintiff representatives [2]. - The lawsuit claims that critical information was withheld from proxy materials, which shareholders needed to make informed decisions [3]. Group 2: Allegations Against Defendants - The complaint alleges that the defendants concealed the true value of Sina's investment in TuSimple, leading to a cash consideration that substantially undervalued the shares [4]. - Internal documents revealed during a related shareholder appraisal proceeding indicated that senior executives knowingly hid the investment's true value, resulting in shareholders receiving less than the worth of their shares at the transaction's closing [5].

Accessibility StatementSkip Navigation PHILADELPHIA, Oct. 27, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) ("MoonLake" or the "Company") on behalf of investors who purchased MoonLake shares during the period of March 10, 2024 through September 29, 2025 (the "Class Period"). Investor Deadline: Investors who purchased MoonLake securities during the Class Period may, no later than December 15, 2025, ...